1Dov A, Abramovitch E, Warwar N, et al. Diminished phospho-diesterase-SB potentiates biphasic insulin response to glucose. Endocrinology, 2008,149:741-748.
2Yaekura K, Julyan R, Wicksteed BL, et al. Insulin secretory deficiency and glucose intolerance in Rab3A null mice. J Biol Chem, 2003,278,9715-9721.
3Doyte M, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev, 2003,55:105-131.
4Park H, Dong X, Fisher TL, et al. Exendin-4 uses Irs 2 signaling to mediate pancreatic β cell growth and function. J Biol Chem, 2006, 281:1159-1168.
5Knoch KP, Meisteffeld R, Kersting S, et al. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in β cells. Cell Metab, 2006,3:123-134.
7De Heer J, Hoist JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes, 2007,56:438-443.
8MacDonald PE, Wheeler MB. Vohage-dependent K^+ channels in pancreatic β cells: role, regulation and potential as therapeutic targets. Diabetologia, 2003,46 : 1046-1062.
9Dyachok O, Isakov Y, Sagetorp J, et al. Oscillations of cyclic AMP in hormone-stimulated insulin-secreting β-cells. Nature, 2006,439 : 349- 352.
10Kang G, Chepumy OG, Rindler MJ, et al. A cAMP and Ca^2+ coincidence detector in support of Ca^2+ -induced Ca^2+ release in mouse pancreatic β cells. J Physiol, 2005,566 : 173-188.
2Edavalath M,Stephens JW.Liraglutide in the treatment of type 2 diabetes mellitus:clinical utility and patient perspectives[J].Patient Prefer Adherence,2010(4):61-68.
3Zinman B,Gerich J,Buse JB,et al.Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD)[J].Diabetes Care,2009,32 (7):1224-1230.
4Garber A,Henry R,Ratner R,et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono):a randomised,52-week,phase Ⅲ,double-blind,parallel-treatment trial[J].Lancet,2009,373(9662):473-481.
5Salehi M,Aulinger BA,D'Alessio DA.Targeting beta-cell mass in type 2 diabetes:promise and limitations of new drugs based on incretins[J].Endocr Rev,2008,29 (3):367-379.
6Nauck M,Frid A,Hermansen K,et al.Efficacy and safety comparison of liraglutide,glimepiride,and placebo,all in combination with metformin,in type 2 diabetes:the LEAD (liraglutide effect and action in diabetes)-2 study[J].Diabetes Care,2009,32(1):84-90.
7Cariou B.Harnessing the incretin system beyond glucose control:potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes[J].Diabetes Metab,2012,38(4):298-308.
8Russell-Jones D.The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes[J].Int J Clin Pract,2010,64(10):1402-1414.
9Lind M.Glucagon-like peptide-1(GLP-1)analogue combined with isulin reduces HbA了c and weight with low risk of hypoglycemia and high treatment satisfaction[J].Primary Care Diabetes,2012,6(1):41-47.
